

REMARKS

Claims 1-6 are pending.

Claims 1 and 2 have been amended to recite oligonucleotides of different length, support for which can be found throughout the specification, particularly on line 6 of page 33. No new matter is added.

The claims are believed to be patentable over the references cited in the prior Office Action because the oligonucleotide mixtures of Southern and Brenner neither contain nor can be readily modified to contain oligonucleotides of different lengths.

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-1078.

Respectfully submitted,

Date: February 19, 2008

By: /James S. Keddie, Reg. No. 48,920/
James S. Keddie
Registration No. 48,920

Agilent Technologies, Inc.
Legal Department, DL429
IP Administration
P.O. Box 7599
Loveland, CO 80537-0599